Innovent Biologics rises 10% after striking up to $10.5 billion oncology deal with Pfizer
Chinese biotech Innovent Biologics rose as much as 10% on Hong Kong's exchange after signing a strategic global licensing and collaboration agreement with US pharma giant Pfizer. The deal covers oncology medicines and includes upfront and milestone payments worth up to $10.5 billion.
CNBC Top NewsAccording to CNBC, Innovent Biologics rose as much as 10% on the Hong Kong exchange after announcing a global licensing and collaboration deal with Pfizer. The main programme covers several targeted-therapy candidates used in cancer treatment. Pfizer payments could reach a total of $10.5 billion, combining upfront amounts with development and commercial milestones.
China's pharmaceutical sector has stood out over the past two years through licensing deals signed with major global drug companies, and analysts say the trend signals a maturing Chinese R&D ecosystem. Innovent chief executive Yongjun Liu said Pfizer's global commercialisation network would speed patient access. On the Pfizer side, executives stressed that the deal strengthens the oncology portfolio and helps balance R&D costs.
Clinical approvals and regulatory milestones will be decisive for the contract's ultimate value. The agreement is expected to advance in parallel with reviews at the US FDA, the European EMA and China's National Medical Products Administration. This article reports facts as published; it does not constitute investment or medical advice.
More from North America
Broadcom shares plunge as software sales lag, AI chip forecast steady
Broadcom reported accelerating AI chip growth, but software sales lagged expectations and the full-year AI chip forecast was left unchanged. Shares fell sharply in after-hours trade. Investors questioned whether the unchanged guidance signals a slowdown in hyperscaler capital spending.
US House votes to constrain Trump's war powers on Iran
The US House of Representatives passed a resolution to restrict President Trump's authority to use military force against Iran without congressional approval. The measure now moves to the Senate, where its fate is uncertain; Trump is expected to veto if it reaches his desk. Oil markets traded volatile on the headline.
US private payrolls grew by 122,000 in May, stronger than expected, ADP reports
US private payrolls rose by 122,000 jobs in May, beating economists' expectations, according to the ADP report. The data suggests the labor market remains resilient as the Federal Reserve reassesses its interest-rate path.